When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Accurately determining a company’s long-term prospects isn’t easy, especially when sentiment is weak. That’s where StockStory comes in - to help you find attractive investment candidates backed by unbiased research. That said, here is one stock where Wall Street’s pessimism is creating a buying opportunity and two facing legitimate challenges.
Two Stocks to Sell:
Amkor (AMKR)
Consensus Price Target: $75.50 (14.2% implied return)
Operating through a largely Asian facility footprint, Amkor Technologies (NASDAQ: AMKR) provides outsourced packaging and testing for semiconductors.
Why Do We Think AMKR Will Underperform?
- Projected sales growth of 11.3% for the next 12 months suggests sluggish demand
- High input costs result in an inferior gross margin of 14.3% that must be offset through higher volumes
- Investment activity picked up over the last five years, pressuring its weak free cash flow margin of 2.9%
Amkor’s stock price of $66.10 implies a valuation ratio of 32x forward P/E. If you’re considering AMKR for your portfolio, see our FREE research report to learn more.
Timken (TKR)
Consensus Price Target: $129.82 (15.2% implied return)
Established after the founder noticed the difficulty freight wagons had making sharp turns, Timken (NYSE: TKR) is a provider of industrial parts used across various sectors.
Why Should You Dump TKR?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
- Waning returns on capital imply its previous profit engines are losing steam
Timken is trading at $112.73 per share, or 18.7x forward P/E. Read our free research report to see why you should think twice about including TKR in your portfolio.
One Stock to Buy:
Clover Health (CLOV)
Consensus Price Target: $3.15 (-6.9% implied return)
Founded in 2014 to improve healthcare for America's seniors through technology, Clover Health (NASDAQ: CLOV) provides Medicare Advantage plans for seniors with a focus on affordable care and uses its proprietary Clover Assistant software to help physicians manage patient care.
Why Is CLOV a Good Business?
- Annual revenue growth of 31.2% over the past two years was outstanding, reflecting market share gains this cycle
- Adjusted operating margin improvement of 25.6 percentage points over the last five years demonstrates its ability to scale efficiently
- Free cash flow margin is now positive, indicating the company has achieved financial self-sustainability
At $3.38 per share, Clover Health trades at 38.6x forward P/E. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
